Outsourcing Pharma

81. During A Tech Transfer, There Is No Substitute For Boots On The Ground 3/7/2018

    Ray Sison, VP of pharmaceutical outsourcing and tech transfer at xCell Strategic Consulting, recounts how one of his tech transfers went bad and the five important points he learned as a result of the experience.

82. Is Your CDMO Listening To Your Small-Company Needs? 3/7/2018

    Small companies can often encounter situations in which contract organizations devote their best people to their larger sponsors. Therefore, to ensure you get the attention your small-company project deserves, you need to take some proactive steps.

83. How Some Sponsors Internally Evaluate Their CDMOs 3/7/2018

    A panel of supply chain experts share best practices and perspectives on what parameters to use in evaluating CMOs/CDMOs, how to address low performance partners, and how to meet growing FDA expectations.

84. When Is Virtual The Right Course Of Action? 3/7/2018

    A look at three scenarios that may impact the decision of virtual or in-house manufacturing, as well as key aspects to consider in the selection process and in forming a strong relationship between the company and CDMO.

85. What Does Data Integrity Mean To Sourcing Professionals? 3/5/2018

    Sourcing professionals spend a great deal of time identifying and vetting suppliers. There are steps you can take early in the process to limit the likelihood of choosing a supplier with a major quality issue, specifically risks associated with data integrity.

86. Virtual And Variable: Two Visions For Biopharma Outsourcing In 2018 12/7/2017

    Deborah Dunsire, CEO of XTuit Pharmaceuticals; and Robert Discordia, executive director, global product development & supply procurement for Bristol-Myers Squibb discuss new approaches to external partnerships in pharma.

87. Finding The Right CRO For Rare Disease Trials 5/9/2017

    CRO selection is a challenge for every company outsourcing clinical trials. When the trial you are about to launch is for a rare genetic disease and has 30 patients spread across several countries and continents, the challenges are multiplied.

88. A Combination of Functional And Full-Service CROs Supports Strategic Outsourcing 8/5/2014

    Outsourcing has become part of the strategy of just about every business in the drug development industry. Subcontracting various procedures along the stages of development to outside firms adds value to the process by reducing fixed costs, shortening timelines, and offering access to external expertise.

89. The Continued Evolution Of The Sponsor-CRO Relationship 8/5/2014

    Not long ago, the dynamic between the sponsor and the CRO was purely that of a client/vendor. Contract research organizations were engaged to reduce fixed labor costs on the sponsor side for work that varied in demand.

90. Use Data To Find And Manage Your CRO Partnerships 8/5/2014

    According to Hurd, there are currently 9 billion devices connected to the Internet, a number that may reach 50 billion by the end of the decade. This will create an absolute explosion of data that businesses, including those in the life sciences, will have to manage. We know going in that a lot of that data will be worthless. Therefore, it will be incumbent upon companies to discern the valuable data from the noise.